CLVS Clovis Oncology Inc

Price (delayed)

$1.7

Market cap

$244.59M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.1

Enterprise value

$775.91M

Clovis Oncology, Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents in the U.S., Europe and additional international markets. Clovis Oncology targets development programs at ...

Highlights
CLVS's EPS is up by 43% YoY and by 8% from the previous quarter
CLVS's net income is up by 23% YoY and by 2.3% from the previous quarter
The equity has contracted by 37% YoY and by 9% from the previous quarter
CLVS's gross profit is down by 11% year-on-year and by 3.3% since the previous quarter

Key stats

What are the main financial stats of CLVS
Market
Shares outstanding
143.88M
Market cap
$244.59M
Enterprise value
$775.91M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
1.62
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
5.35
Earnings
Revenue
$144.95M
EBIT
-$223.64M
EBITDA
-$215.46M
Free cash flow
-$192.92M
Per share
EPS
-$2.1
Free cash flow per share
-$1.4
Book value per share
-$2.13
Revenue per share
$1.05
TBVPS
$2.38
Balance sheet
Total assets
$451.53M
Total liabilities
$754.84M
Debt
$653.56M
Equity
-$303.31M
Working capital
$63.7M
Liquidity
Debt to equity
-2.15
Current ratio
1.52
Quick ratio
1.23
Net debt/EBITDA
-2.47
Margins
EBITDA margin
-148.6%
Gross margin
73.4%
Net margin
-178.3%
Operating margin
-150.5%
Efficiency
Return on assets
-51.6%
Return on equity
N/A
Return on invested capital
-30.9%
Return on capital employed
-67.8%
Return on sales
-154.3%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

CLVS stock price

How has the Clovis Oncology stock price performed over time
Intraday
-2.3%
1 week
44.07%
1 month
169.8%
1 year
-72.97%
YTD
-37.27%
QTD
-15.84%

Financial performance

How have Clovis Oncology's revenue and profit performed over time
Revenue
$144.95M
Gross profit
$106.32M
Operating income
-$218.12M
Net income
-$258.42M
Gross margin
73.4%
Net margin
-178.3%
CLVS's net income is up by 23% YoY and by 2.3% from the previous quarter
The operating income has increased by 22% YoY and by 3.4% from the previous quarter
Clovis Oncology's net margin has increased by 15% YoY
The operating margin has grown by 13% YoY

Growth

What is Clovis Oncology's growth rate over time

Valuation

What is Clovis Oncology stock price valuation
P/E
N/A
P/B
N/A
P/S
1.62
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
5.35
CLVS's EPS is up by 43% YoY and by 8% from the previous quarter
The equity has contracted by 37% YoY and by 9% from the previous quarter
CLVS's P/S is 94% below its 5-year quarterly average of 25.4 and 44% below its last 4 quarters average of 2.9
Clovis Oncology's revenue has decreased by 9% YoY and by 2.6% QoQ

Efficiency

How efficient is Clovis Oncology business performance
Clovis Oncology's return on invested capital has increased by 27% YoY and by 3.7% QoQ
CLVS's ROS is up by 20% YoY
The company's return on assets rose by 9% YoY but it fell by 2.6% QoQ

Dividends

What is CLVS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CLVS.

Financial health

How did Clovis Oncology financials performed over time
The company's total assets is 40% lower than its total liabilities
The company's total assets fell by 18% YoY and by 4.5% QoQ
The quick ratio has contracted by 10% from the previous quarter
The equity has contracted by 37% YoY and by 9% from the previous quarter
The company's debt to equity rose by 29% YoY and by 6% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.